Melanoma In Situ—Getting the Diagnosis and Prognosis Right
JAMA Dermatology · 01.07.2023 · 159 (7) · 699
DOI: 10.1001/jamadermatol.2023.1485 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA Dermatology, erschienen am 01.07.2023. Verfasst von Anne E Cust und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
- Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.
- Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
Zitieren
APA
Cust, A. E., & Scolyer, R. A. (2023). Melanoma In Situ—Getting the Diagnosis and Prognosis Right. JAMA Dermatology, 159(7), 699. https://doi.org/10.1001/jamadermatol.2023.1485
Vancouver
Cust AE, Scolyer RA. Melanoma In Situ—Getting the Diagnosis and Prognosis Right. JAMA Dermatology. 2023;159(7):699. doi:10.1001/jamadermatol.2023.1485
BibTeX
@article{Cust2023,
author = {Cust, Anne E and Scolyer, Richard A},
title = {Melanoma In Situ—Getting the Diagnosis and Prognosis Right},
journal = {JAMA Dermatology},
year = {2023},
volume = {159},
number = {7},
pages = {699},
doi = {10.1001/jamadermatol.2023.1485}
}
EUVIMED